Press Releases
Cardiovascular Drugs Market to Reach a Value of Approximately US$ 91.0 Billion by 2025

Cardiovascular Drugs Market

, 14 March 2018 -- Cardiovascular diseases (CVDs) comprise disorders and conditions related to circulatory system which include heart and vascular system.

The global cardiovascular drugs market was valued at approximately US$ 80.0 Bn in 2016 is projected to register cumulative annual growth rate (CAGR) of over 1.0% from 2017 to 2025, according to a new report published by Transparency Market Research (TMR) titled “Cardiovascular Drugs Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2017–2025”. The report suggests that surge in incidences of hypertension and hyperlipidemia is likely to spur the demand of cardiovascular drugs in the coming years (2017 to 2025). As key players introduce their new cardiovascular drugs in developed markets such a North America and Western Europe, these regions are likely to account for dominating share of the global cardiovascular drugs market. Changing dietary habits and sedentary lifestyle trends in emerging markets such as China and India is likely to boost growth of Asia Pacific cardiovascular drugs market at a CAGR of around 2.0% from 2017 to 2025.

Request for Sample Copy of Report @

Cardiovascular diseases (CVD’s) are the leading cause of deaths across the globe. According to World Health Organization’s report, more than 17.7 million individuals died of CVDs in 2015, and CVDs accounted for 31% of total deaths in 2013. Cardiovascular diseases are one of the leading cause for healthcare burden in developed as well as developing countries. Sedentary lifestyle, lack of exercise and changing dietary habits in developed and emerging markets is leading to cardiovascular diseases such as hypertension and hyperlipidemia which in turn is likely to fuel uptake of cardiovascular drugs. Many of the block buster cardiovascular drugs have lost their patent exclusivity in recent years and many are about to go off patent in near future. This factor has attracted many small and mid-size industry players to offer their generic drugs, which in turn has attributed for devaluation of the market, there by restraining growth of global cardiovascular drugs market.

The report offers detailed segmentation of global cardiovascular drugs market based on drug class, indication and distribution channel. Among the drug class studied, anti-clotting agents segment is poised to account for leading share of the global market during the forecast period from 2017 to 2025. Anti-clotting agents segment which comprises anticoagulants and platelet aggregation inhibitors is likely to get boost from increasing incidences of heart failures, stroke, etc. According to Center for Disease Control and Prevention of the U.S., around 795,000 people in the U.S. suffer from a stroke each year of which 610,000 are found to be first or new cases of stroke. The renin-angiotensin system blockers segment is anticipated to lose its market share during the forecast period, and is expected to hold a share of ~16.0% by 2025 from ~18.0% in 2016. Availability of generics and adverse effects associated with ACE inhibitors and ARB’s are factors likely to hamper this segment.

Enquiry for discount on this report @

Among indications, hypertension segment is projected to hold dominant share of global cardiovascular drugs market during the forecast period and is likely to expand at CAGR of around 1.5% from 2017 to 2025. Center for Disease Control and Prevention of the U.S. states that ~32% of ##### population in the U.S. had high blood pressure in 2012. Surge in preference for hypertension specific drugs such as Tracleer, Letairis, etc. over conventional beta blockers, diuretics and calcium channel blockers is projected to fuel this expansion. Arrhythmia segment, which accounted for a meager share of global cardiovascular drugs market is anticipated to have substantial growth and account for approximately 4.0% of market share by 2025. Advancements in implantable cardiovascular devices such as leadless pacemakers, development of battery free pacemakers to treat arrhythmia is likely to hamper arrhythmia drugs market. Retail pharmacies are projected to be leading segment of distribution channel over the forecast period while online pharmacies are likely to register growth at CAGR of over 2.0% from 2017 to 2025. Adoption of e-commerce, convenience & discounts offered by mail pharmacies are major factors triggering this growth.

In terms of value, North America was leading contributor in global cardiovascular drugs market in 2016. High prevalence of hyperlipidemia and hypertension in the U.S. is one of the contributing factor for major share of the North America market. However, increasing foray of generic drugs in the U.S. is implying pricing constraints on existing players which is likely to hamper this market. According to the Association for Accessible Medicines of the U.S., approximately 89% of the total prescriptions dispensed in 2016 in the U.S. were contributed by generic drugs. Healthcare spending in emerging markets such as China and India are rising, which is fueling the expansion of Asia Pacific cardiovascular drugs market. Regaining economic growth in Latin American markets such as Brazil is augmenting healthcare expenditure through rise in private health insurance, entry of international drug manufacturers and health care providers in this region. This factor is likely to propel Latin America cardiovascular drugs market at CAGR of 1.9% from 2017 to 2025.

Report Overview @

The report also provide profiles of leading players operating in global cardiovascular drugs market include AstraZeneca plc., Pfizer Inc., Novartis AG, Merck & Co., Inc., Bristol-Myers Squibb Company, Bayer AG, Sanofi, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd, Abbott Laboratories, Gilead Sciences, Inc., Johnson & Johnson, Astellas Pharma, Inc., Eli Lilly and Company, Otsuka Holdings Co., Ltd. and Takeda Pharmaceutical Company Limited. Expansion of cardiovascular drugs portfolio through improving existing drugs and developing new drug molecules is one of the key strategy adopted by many key players, recent developments and launch of biological drugs such as PCSK9 for treating hyperlipidemia by Sanofi, Pfizer Inc. and other key players reflect these strategies

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453

# # #

Submitted by hawer on Wednesday, 14 March 2018 at 2:54 PM
Category: Health Care & Medical
Related News

Radiation Dose Management Market to Register CAGR of Over 9.0% from 2017 to 2025
Tuesday, 20 Mar 2018

Breast Imaging Equipment Market Segmentation Detailed Study with Forecast to 2025
Tuesday, 20 Mar 2018

Joint Reconstruction Device Market Review with Forecast Research Report 2017 - 2025
Tuesday, 20 Mar 2018

Venturi Mask Market Latest Report with Forecast to 2025
Tuesday, 20 Mar 2018

Blood Plasma Derivatives Market Trends and Segments 2017 - 2025
Tuesday, 20 Mar 2018

Related Events

Imaging in Hawaii
Monday, 19 Mar 2018

9th Proactive GCP Compliance
Monday, 19 Mar 2018

The International ADHD Congress (ADHD 2018)
Monday, 19 Mar 2018

ICI Boston Summit
Monday, 19 Mar 2018

ISPE 2018 Europe Annual Conference
Monday, 19 Mar 2018

Latest News

Transporting Seniors Is Made Easier And Professional By Care Conextion
Wednesday, 21 Mar 2018

Kugali Anthology Project On Kickstarter Generates Global Interest On African Tales
Wednesday, 21 Mar 2018

Product sampling New York to establish trust
Wednesday, 21 Mar 2018

Radiation Dose Management Market to Register CAGR of Over 9.0% from 2017 to 2025
Tuesday, 20 Mar 2018

Kugali Anthology Kickstarter Project Wins Remarkable Feedback From Contributors
Tuesday, 20 Mar 2018

Want to get your press releases, event listings, and job ads on Scoopasia? Register now for a FREE account or login if you already have one!
Scoopasia v1.0b. Copyright © 2018
Today is Wednesday, 21 March 2018

About Scoopasia | FAQ | Privacy Policy | Contact Us

Press Releases
Event Listings
Job Listings
Arts & Entertainment
Architecture & Construction
Automotive & Travel
Consumer Technology
Enterprise Technology
Food & Fashion
Government & Policy
Health Care & Medical
News & Media
Science & Research
Sports & Fitness
Login / Register
Get Scoopasia through RSS Feeds & Email Notifications!

Journalist's Toolbox
Hello journalist, welcome to Scoopasia--a powerful online resource for media information in Asia. Scoopasia has press releases and media events for every beat and industry. All content on Scoopasia is 100% FREE. You don't even need to login!

  • Scoop Line
    (Instant Information Request)
    The easiest way to ask questions and request information from the PR community.

  • Advanced Search
    Drill down, dig deep, for media information the way you want it.

  • Journalist's Resources
    Resources and tools you can't do without.

  • PR Tools
    Scoopasia Blog Search
    Search the largest handpicked collection of Asia's most prominent and influential blogs.

  • PR Bookmarks
  • Web 2.0 Bookmarks
  • Media Bookmarks

    More Coming Soon...

  • Upcoming Events
  • Argus California Carbon and LCFS Summit
  • Imaging in Hawaii
  • 9th Proactive GCP Compliance
  • The International ADHD Congress (ADHD 2018)
  • ICI Boston Summit

  • Latest Jobs
    Sorry, there are currently no entries posted here.